Page last updated: 2024-08-24

bmy 25067 and Neoplasms

bmy 25067 has been researched along with Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ganesan, TS; Green, JA; Harris, AL; LaCreta, FP; Macaulay, VM; McKinley, L; O'Byrne, KJ; Philip, PA; Talbot, DC; Winograd, B1
de Boer-Dennert, M; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; Verweij, J; Winograd, B1

Trials

2 trial(s) available for bmy 25067 and Neoplasms

ArticleYear
Phase I study of the mitomycin C analogue BMS-181174.
    British journal of cancer, 1998, Volume: 77, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Heart; Humans; Kidney; Lung; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms; Thrombophlebitis

1998
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
    Anti-cancer drugs, 1999, Volume: 10, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Neoplasms; Vascular Diseases

1999